Perigon Wealth Management LLC Buys Shares of 85,185 Sera Prognostics, Inc. (NASDAQ:SERA)

Perigon Wealth Management LLC acquired a new position in Sera Prognostics, Inc. (NASDAQ:SERA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 85,185 shares of the company’s stock, valued at approximately $509,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Sera Prognostics by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 786,792 shares of the company’s stock worth $1,463,000 after purchasing an additional 13,364 shares during the period. Sanders Morris Harris LLC grew its holdings in shares of Sera Prognostics by 22.6% during the 3rd quarter. Sanders Morris Harris LLC now owns 445,105 shares of the company’s stock worth $828,000 after purchasing an additional 81,933 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Sera Prognostics by 59.3% during the fourth quarter. Captrust Financial Advisors now owns 379,237 shares of the company’s stock valued at $478,000 after purchasing an additional 141,138 shares during the period. BlackRock Inc. raised its stake in shares of Sera Prognostics by 4.9% in the first quarter. BlackRock Inc. now owns 186,140 shares of the company’s stock valued at $707,000 after purchasing an additional 8,718 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Sera Prognostics by 17.7% in the first quarter. Geode Capital Management LLC now owns 145,486 shares of the company’s stock worth $557,000 after purchasing an additional 21,919 shares during the period. Institutional investors own 54.64% of the company’s stock.

Insider Buying and Selling at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 27,997 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total transaction of $224,815.91. Following the completion of the sale, the chief executive officer now owns 947,003 shares in the company, valued at approximately $7,604,434.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Paul Kearney sold 4,984 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $40,021.52. Following the completion of the sale, the insider now owns 160,066 shares of the company’s stock, valued at $1,285,329.98. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Zhenya Lindgardt sold 27,997 shares of the company’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $224,815.91. Following the transaction, the chief executive officer now directly owns 947,003 shares in the company, valued at approximately $7,604,434.09. The disclosure for this sale can be found here. Over the last three months, insiders sold 141,335 shares of company stock valued at $1,255,192. 15.60% of the stock is currently owned by company insiders.

Sera Prognostics Price Performance

Shares of Sera Prognostics stock opened at $10.04 on Tuesday. The company’s fifty day moving average price is $9.20 and its two-hundred day moving average price is $5.74. Sera Prognostics, Inc. has a 52-week low of $1.52 and a 52-week high of $11.32.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25). Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 45.74%. The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.94 EPS for the current year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.